Scientific Reports (May 2022)

Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection

  • Eik Schäfer,
  • Christian Scheer,
  • Karen Saljé,
  • Anja Fritz,
  • Thomas Kohlmann,
  • Nils-Olaf Hübner,
  • Matthias Napp,
  • Lizon Fiedler-Lacombe,
  • Dana Stahl,
  • Bernhard Rauch,
  • Matthias Nauck,
  • Uwe Völker,
  • Stephan Felix,
  • Guglielmo Lucchese,
  • Agnes Flöel,
  • Stefan Engeli,
  • Wolfgang Hoffmann,
  • Klaus Hahnenkamp,
  • Mladen V. Tzvetkov

DOI
https://doi.org/10.1038/s41598-022-11103-0
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 12

Abstract

Read online

Abstract We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough (51.8%). Loss of smell (anosmia), loss of taste (ageusia), dyspnea, and productive cough were reported with an onset of 4 days. Anosmia or ageusia were reported by only 18% of the participants at day one, but up to 49% between days 7 and 9. Not all participants who reported ageusia also reported anosmia. Individuals suffering from ageusia without anosmia were at highest risk of hospitalization (OR 6.8, 95% CI 2.5–18.1). They also experienced more commonly dyspnea and nausea (OR of 3.0, 2.9, respectively) suggesting pathophysiological connections between these symptoms. Other symptoms significantly associated with increased risk of hospitalization were dyspnea, vomiting, and fever. Among basic parameters and comorbidities, age > 60 years, COPD, prior stroke, diabetes, kidney and cardiac diseases were also associated with increased risk of hospitalization. In conclusion, due to the delayed onset, ageusia and anosmia may be of limited use in differential diagnosis of SARS-CoV-2. However, differentiation between ageusia and anosmia may be useful for evaluating risk for hospitalization.